Analysis of Genetic Variation of rs2278961 Marker in COLQ Gene as an Informative Marker for Molecular Diagnosis of Congenital Myasthenic Syndrome  in the Isfahan population

Moeinifar, Nafise; Vallian, Sadeq

Document Type : Original Article

Authors

Professor - university of isfahan

Abstract

Abstract
Background: Congenital myasthenic syndromes (CMS) recognized as heterogeneous disorders arising from presynaptic, synaptic, or postsynaptic defects. Congenital myasthenic syndrome due to defects in synaptic activity of the acetylcholinesterase enzyme (AChE) is caused by recessive mutations in the COLQ gene. Ideal method for molecular diagnosis of this disease is direct analysis of the gene mutations, which is expensive and time consuming. Therefore, alternative methods such as linkage analysis using polymorphic markers including single nucleotide polymorphism (SNP) is suggested.
Materials and Methods: In this study, using bioinformatic analysis, rs2278961 marker located on 3'UTR of COLQ gene was selected which contains 2 alleles G and A. rs2278961 marker was genotyped in the Isfahan population by ARMS PCR technique, using specific primers. Degree of heterozygosity and allelic frequencies were calculated by Genepop software. Finally, the amount of polymorphism information content (PIC) was computed by PIC Calculator software.
Results: According to the results of Genepop and PIC Calculator, the frequency of recessive allele A (MAF), the degree of heterozygosity and the PIC were estimated 0.539, 0.61842105 and 0.3735, respectively.
Conclusion: Since the MAF>0.2 and PIC close to 0.375 are the criteria for an efficient marker, rs2278961 having mentioned conditions, therefore it could be suggested as an appropriate markers for diagnosis of CMS disease in Iranian population.

Keywords

Main Subjects

genetics

References

[1]. Ohno K, Ohkawara B, Ito M, Engel AG. Molecular genetics of congenital myasthenic syndromes. eLS. 2014.

[2]. Engel AG. Congenital myasthenic syndromes. Journal of Child Neurology. 1988; 3(4): 233-46.

[3]. Engel A. The scientific basis of myology En: engel AG and banker BQ (eds). Myology Basic and Clinical. New York. McGraw-Hill. 1986.

[4]. Matlik HN, Milhem RM, Saadeldin IY, Al-Jaibeji HS, Al-Gazali L, Ali BR. Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family. Pediatric Neurology. 2014; 51(1): 165-9.

[5]. Bon S, Ayon A, Leroy J, Massoulié J. Trimerization domain of the collagen tail of acetylcholinesterase. Neurochemical Research. 2003; 28(3-4): 523-35.

[6]. Ohno K, Ohkawara B, Ito M. Recent advances in congenital myasthenic syndromes. Clinical and Experimental Neuroimmunology. 2016; 7(3): 246-59.

[7]. Harper CM. Congenital myasthenic syndromes. Seminars in Neurology. 2004; Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

[8]. Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. The Lancet Neurology. 2015; 14(4): 420-34.

[9]. Cruz PMR, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. Current Opinion in Neurology. 2014; 27(5): 566-75.

[10].Hantaï D, Richard P, Koenig J, Eymard B. Congenital myasthenic syndromes. Current Opinion in Neurology. 2004; 17(5): 539-51.

[11].Shapira Y, Sadeh M, Bergtraum M, Tsujino A, Ohno K, Shen XM, et al. Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology. 2002; 58(4): 603-9.

[12].Donger C, Krejci E, Serradell AP, Eymard B, Bon S, Nicole S, et al. Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). The American Journal of Human Genetics. 1998; 63(4): 967-75.

[13].Ohno K, Brengman J, Tsujino A, Engel AG. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proceedings of the National Academy of Sciences. 1998; 95(16): 9654-9.

[14].Palace J, Beeson D. The congenital myasthenic syndromes. Journal of Neuroimmunology. 2008; 201: 2-5.

[15].Kruglyak L, Nickerson DA. Variation is the spice of life. Nature Genetics. 2001; 27(3): 234-5.

[16].Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nature Genetics. 2003; 33: 228-37.

[17].Fazeli Z, Vallian S. Molecular phylogenetic study of the Iranians based on polymorphic markers. Gene. 2013; 512(1): 123-6.

[18].Collins A, Ke X. Primer1: primer design web service for tetra-primer ARMS-PCR. The Open Bioinformatics Journal. 2012; 6: 55-8.

[19].Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. Journal of Heredity. 1995; 86(3): 248-9.

[20].Elston RC. Polymorphism information content. Encyclopedia of Biostatistics. 2005.

[21].Hildebrand CE, David C, Torney C, Wagner P. Informativeness of polymorphic DNA markers. The Human Genome Project: deciphering the blueprint of heredity University Science Books, CA, USA. 1994: 100-2.

[22].Eymard B, Hantai D, Estournet B. Congenital myasthenic syndromes. Handbook of Clinical Neurology. 2012; 113: 1469-80.

[23].Engel AG. Congenital myasthenic syndromes in 2012. Current Neurology and Neuroscience Reports. 2012; 12(1): 92-101.

[24].Siva N. 1000 Genomes project. Nature Biotechnology. 2008; 26(3): 256.

Journal of Sabzevar University of Medical Sciences

Analysis of Genetic Variation of rs2278961 Marker in COLQ Gene as an Informative Marker for Molecular Diagnosis of Congenital Myasthenic Syndrome in the Isfahan population

References

References

Volume 25, Issue 3
July and August 2018
Pages 335-341

Analysis of Genetic Variation of rs2278961 Marker in COLQ Gene as an Informative Marker for Molecular Diagnosis of Congenital Myasthenic Syndrome in the Isfahan population

References

References

Volume 25, Issue 3July and August 2018Pages 335-341

Volume 25, Issue 3
July and August 2018
Pages 335-341